_TOP_ Download Grifols Donor Hub

Safeguarding the health and safety of donors is an absolute top priority for us. Only qualified individuals may donate, and only after providing informed consent complying with local regulations covering areas such as donation frequency, data privacy and personal data protection.

Grifols compensates donors in recognition of their commitment to donating regularly and the time and effort involved. Specific remuneration, which depends on the socioeconomic context of each country, state or donor center, is considered supplementary and not an employment wage.

Download Grifols Donor Hub

DOWNLOAD 🔥 https://ssurll.com/2y4Cqy 🔥

The health and safety of all Grifols center donors and employees is our top priority. We follow all COVID-19 protocols recommended by the Centers for Disease Control and Prevention (CDC). As the CDC changes its recommendations, our centers quickly update our policies and procedures to maintain health and safety.

Americans who have recovered from COVID-19 may help save others from the disease by donating their convalescent plasma at the University of North Carolina in Chapel Hill, or at plasma donor sites operated elsewhere around the country by the global biotherapeutics company Grifols.

Grifols, which has more than 2,000 employees in North Carolina, has begun identifying, screening and selecting volunteer donors who have recovered from COVID-19 to donate their plasma in select U.S. cities, none currently in N.C. UNC-TV aired this short video featuring the Grifols plasma collection system.

The University of North Carolina Convalescent Plasma Task Force at the UNC Medical Center in Chapel Hill, however, is collecting convalescent plasma from donors to treat patients critically ill with COVID-19.

Eligible donors must have tested positive for COVID-19 (PCR positive swab) and be at least 14 days from the resolution of symptoms. If individuals are between 14 and 28 days from onset of symptoms, they would need to receive a second COVID-19 swab to confirm that they test negative.

Currently, Grifols is focusing on collecting convalescent plasma from donors in cities that had a high number of COVID-19 cases earlier in the outbreak. These cities and their surrounding areas include Chicago, Dallas, Houston, Los Angeles, San Antonio, San Diego and Seattle. The Raleigh donation center location is not currently accepting the COVID-19 convalescent plasma, according to a company representative at the site.

The company said additional cities will be added in the future. It has a network of about 300 U.S. Food and Drug Administration-approved plasma donor centers nationally. The company said it will build a new facility in Clayton to process the collected convalescent plasma.

Recovered COVID-19 individuals interested in donating in the select cities should call 1-866-END-CV19 where Grifols specialists will pre-screen potential donors and direct them to their local Grifols plasma donor center.

"We are deeply saddened by yesterday's tragic incident at our Pittsburgh plasma donor center. The safety of our employees and donors is always our first priority. Two of our beloved employees lost their lives and our thoughts and prayers go out to their families and loved ones. We are grateful to the first responders and our employees who acted quickly to prevent any additional injuries. Biomat USA is cooperating with the local authorities as the investigation continues."

Plasma is needed today, more than ever, to meet the growing demand for life-saving plasma-derived medicines. Grifols will launch a highly targeted, multi-channel campaign to raise awareness of plasma donation and attract new donors into its centers.

Plasma contains essential proteins and antibodies that help our bodies properly function. Without enough of any one of these proteins, a person could have or develop a life-threatening illness. Every time a person gives plasma at a Grifols donor center, it goes toward helping people globally who have no other alternative than plasma-derived medicines to lead healthier lives.

Background and objectives: LDL apheresis is used to treat patients with familial hypercholesterolaemia, and low-volume plasmapheresis for plasma donation may similarly lower cholesterol levels in some donors. This study was designed to assess the effect of plasmapheresis on total, LDL and HDL cholesterol levels in a plasma donor population.

Materials and methods: This was a prospective, unblinded longitudinal cohort study in which a blood sample was obtained for analysis before each donation. Data from 663 donors were analysed using a multivariable repeated measures regression model with a general estimating equations approach with changes in cholesterol as the primary outcome measure.

The quality and safety of ALPHANATE begins with the collection of plasma, long before the manufacturing process even starts. Each potential donor must pass 2 medical exams and 2 plasma tests over a 6-month period. If the donor passes, he or she then must pass a health screening at each visit as well as an annual physical exam.

Each unit of plasma is tested after each collection using FDA-approved protocols to verify the donor's health status and determine the safety of the collected plasma. To help ensure safety, no plasma from any one-time donor is ever used in the manufacuring of ALPHANATE.

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company with a track-record of more than 75 years improving people's health and well-being, has completed the acquisition of the NAT (Nucleic Acid Testing) donor screening unit from the U.S. company Hologic for a purchase price of USD 1,850 million (EUR 1,750 million).

Currently, Grifols employs more than 10,500 people in the U.S., where the company has two production facilities in Los Angeles (California) and one in Clayton (North Caroline) to produce plasma-derived medicines; two centralized plasma analysis laboratories in San Marcos and Austin (Texas); and a network of over 160 plasma donor centers distributed throughout the United States.

The company also has a manufacturing plant in Emeryville (San Francisco, California) for the production of antigens for immunological diagnostic. Following the acquisition of the Hologic's share of the NAT donor screening unit, it also has a manufacturing plant in San Diego (California).

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE: GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information, visit www.grifols.com e24fc04721